Login to Your Account

$365M Deal Hands Millennium Ex-U.S. Rights for CD30 Drug

By Donna Young

Wednesday, December 16, 2009
As predicted last week by analysts, Seattle Genetics Inc. landed a cozy global development and commercialization deal for its Hodgkin's lymphoma drug brentuximab vedotin (SGN-35), potentially worth more than $365 million, including $60 million up front, plus tiered double-digit royalties, which Needham & Co. analyst Mark Monane called a "nice warm deal as the weather gets colder." (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription